Published in Biochim Biophys Acta on August 29, 2008
Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res (2011) 1.37
Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res (2012) 1.14
Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med (2009) 0.93
Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells. FEBS Lett (2013) 0.90
Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol Cell Proteomics (2010) 0.86
Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. Am J Cancer Res (2012) 0.82
Temporal expression of Pelp1 during proliferation and osteogenic differentiation of rat bone marrow mesenchymal stem cells. PLoS One (2013) 0.80
Increased PELP1 expression in rat periodontal ligament tissue in response to estrogens treatment. J Mol Histol (2013) 0.79
Simvastatin suppresses breast cancer cell proliferation induced by senescent cells. Sci Rep (2015) 0.79
Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer. J R Soc Interface (2014) 0.78
The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis. Carcinogenesis (2015) 0.77
Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer. Oncogene (2016) 0.75
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology (2007) 2.45
Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol (2002) 2.19
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res (2002) 1.95
Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res (2005) 1.84
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res (2005) 1.38
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene (2002) 1.33
90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J (2004) 1.33
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene (2004) 1.28
Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res (2006) 1.20
Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res (2009) 1.19
Effects of light and food schedules on liver and tumor molecular clocks in mice. J Natl Cancer Inst (2005) 1.16
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res (2002) 1.16
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia (2009) 1.15
Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res (2008) 1.14
PTP-PEST phosphatase variations in human cancer. Cancer Genet Cytogenet (2006) 1.10
Fucans, but not fucomannoglucuronans, determine the biological activities of sulfated polysaccharides from Laminaria saccharina brown seaweed. PLoS One (2011) 1.05
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer (2006) 1.04
Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res (2007) 1.04
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology (2005) 1.01
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett (2008) 1.00
Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res (2006) 0.99
Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer (2004) 0.98
Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res (2009) 0.96
Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. J Cell Physiol (2006) 0.95
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res (2006) 0.93
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. Transl Oncol (2013) 0.92
Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer (2012) 0.92
A dietary tomato supplement prevents prostate cancer in TRAMP mice. Cancer Prev Res (Phila) (2010) 0.92
LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med (Berl) (2012) 0.90
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost (2010) 0.89
Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy. Int J Cancer (2012) 0.89
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers (Basel) (2013) 0.89
Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol (2011) 0.88
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. Breast Cancer Res Treat (2014) 0.88
Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib. Chronobiol Int (2009) 0.86
An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. Curr Cancer Drug Targets (2012) 0.86
P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations. J Cell Physiol (2008) 0.86
Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int (2011) 0.85
Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS One (2011) 0.85
Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). Int J Cancer (2010) 0.85
Role of pleckstrin homology domain in regulating membrane targeting and metabolic function of insulin receptor substrate 3. Mol Endocrinol (2003) 0.84
Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice. Clin Colorectal Cancer (2012) 0.84
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer (2013) 0.84
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol (2002) 0.84
Developing a decision-making model based on an interdisciplinary oncological care group for the management of colorectal cancer. Anticancer Res (2014) 0.83
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. Int J Cancer (2009) 0.82
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. J Cancer Res Clin Oncol (2012) 0.82
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. Breast Cancer Res Treat (2008) 0.82
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer. J Clin Oncol (2007) 0.82
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori (2012) 0.81
Tumor-derived microvesicles: the metastasomes. Med Hypotheses (2012) 0.81
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. Endocrinology (2004) 0.80
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. Endocrinology (2007) 0.79
Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy. Cancer Manag Res (2013) 0.78
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. Mol Cancer Ther (2014) 0.78
Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study. J Oncol Pharm Pract (2012) 0.78
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. J Invest Dermatol (2002) 0.77